Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Efficacy and Safety of Combination Therapies With Oseltamivir & Zanamivir or Oseltamivir & Amantadine Versus Oseltamivir Monotherapy in the Treatment of Seasonal Influenza A Infection

This study has been terminated.
Sponsor:
Information provided by:
Hospices Civils de Lyon
ClinicalTrials.gov Identifier:
NCT00830323
First received: January 26, 2009
Last updated: September 29, 2010
Last verified: October 2009
  Purpose

Neuraminidase inhibitors (NAI) are effective anti-influenza antiviral treatment. During their use in experimentally infected patients, it has been shown that the viral load detected in the nasal fluid is decreasing significantly faster than in non treated patients. During clinical practice, the emergence of NAI-resistant strains has been observed. These strains remain rare, but their emergence seemed to be related to the mis-use of the NAI products (insufficient duration or dosage). This observation as well as the detection of NAI-resistant viruses in the community raises concerns about putative emergence of resistant clones in the specific context of a pandemic, when the use of NAI will be very large in the aim of reducing transmission, and subsequently the impact of the emerging virus.

In this context, it is important to determine the putative interest of alternative strategies.

Although zanamivir and oseltamivir are both issued from the same class , this combination may lead to a more rapid viral clearance in the infected cases, and to a reduction in the emergence of resistant sub-clones, and alternatively, might lead to a competitive inhibition. The evaluation of these combinations needs to be conducted in vivo.

Among available anti influenza antivirals, M2 blockers have been previously used. Although their efficacy against A H5N1 remains to be ascertained, their use in combination with NAI should also be evaluated in the context of a preparation for a possible pandemic and determination of the stockpile.

Therefore, the evaluation of combination therapies in the treatment of a virologically suspected influenza will be investigated in primary care during the winter season 2008-2009.


Condition Intervention Phase
Influenza A Infection
Drug: oseltamivir + zanamivir
Drug: oseltamivir+ amantadine
Drug: oseltamivir
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Efficacy and Safety of Combination Therapies With Oseltamivir & Zanamivir or Oseltamivir & Amantadine Versus Oseltamivir Monotherapy in the Treatment of Seasonal Influenza A Infection

Resource links provided by NLM:


Further study details as provided by Hospices Civils de Lyon:

Primary Outcome Measures:
  • describe the antiviral efficacy in the 3 arms in the treatment of seasonal influenza infection as assessed by negative viral detection in nose swabs at the fifth swab [H48±3] [ Time Frame: 48 hours ] [ Designated as safety issue: No ]
  • Describe the antiviral efficacy in 3 arms in the treatment of seasonal influenza infection as assessed by negativity of RT-PCR for viral RNA in nose and throat swabs at the 5th swab [H48±3] and at the 7th swab [H84±3]. [ Time Frame: 84 hours ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Describe the antiviral efficacy in combination therapy arms (1,2) and in monotherapy arm (3) in the treatment of seasonal influenza infection as assessed by time to sustained negativity of RT-PCR for viral RNA or viral culture in any sample. [ Time Frame: 168 hours ] [ Designated as safety issue: No ]
  • Assess viral replication dynamics (duration and level of viral replication) in the respiratory tract in the combination and standard-dose cohorts. [ Time Frame: 168 hours ] [ Designated as safety issue: No ]
  • Assess the frequency, genetic basis, and duration of antiviral resistance to each arm during and after therapy [ Time Frame: 168 hours ] [ Designated as safety issue: No ]
  • Describe the time to alleviation of illness in the 3 arms defined as the time from the beginning of the study treatment to the time that 7 typical key symptoms of natural influenza had reduced to absent or mi [ Time Frame: 168 hours ] [ Designated as safety issue: No ]
  • Describe the tolerability of combination and in standard-dose arms as assessed by clinical adverse events that are possibly or probably related to each single agent (Incidence and duration) [ Time Frame: 168 hours ] [ Designated as safety issue: No ]

Estimated Enrollment: 60
Study Start Date: January 2009
Estimated Study Completion Date: August 2009
Estimated Primary Completion Date: August 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: oseltamivir + zanamivir
oseltamivir (75mg bd for 5 days, oral) zanamivir (5mg bd for 5 days, inhaled by mouth)
Experimental: Arm 2 Drug: oseltamivir+ amantadine
oseltamivir (75mg bd for 5 days, oral) + amantadine (100mg bd for 5 days, oral)
Active Comparator: Arm 3 Drug: oseltamivir
oseltamivir (75mg bd for 5 days, oral)

Detailed Description:

Study Schedule:

  • Patient's follow up: 7 days with 10 visits V1, V2, V3, V4, V5 every 12 hours V6, V7, V8, V9, V10 every 24 hours
  • V1: conducted by the GP rapid test diagnostic for influenza A, urine pregnancy test for women, inclusion /randomisation, nasal sample, initiation of treatment.
  • V2 to V9: conducted by a nurse at the patient's home; nasal sample, symptoms scoring, safety assessment (side effects)
  • V 10: conducted by GP; medical evaluation (follow up evaluation)
  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Influenza season declared
  • Subjects aged>18 years and < 65 years presenting within 36h documented of onset influenza illness
  • Who have fever >38°C
  • Who present at least one of the following respiratory symptoms (cough, sore throat, nasal symptoms), and one of the following constitutional symptoms (headache, myalgia, sweats and or chills or fatigue)
  • Positive rapid diagnostic test for influenza A
  • Who have giving written informed consent prior to enrollment
  • Patient examined before the inclusion
  • Primary care follow up

Exclusion Criteria:

  • Influenza Vaccination in the 12 months prior the beginning of the study
  • Asthma, Chronic bronchitis
  • Woman with a positive urine pregnancy test
  • Active breast feeding
  • Woman without contraception
  • Clearance of creatinine< 30 ml/min Chronic renal disease
  • History of depression, psychiatric disorders, epilepsy
  • Patients receiving cortocosteroids, immunosuppressants or antipsychotic antiemetic drugs
  • Known oseltamivir or zanamivir hypersensibility
  • Non member of the social security or CMU
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00830323

Locations
France
Hospices civils de Lyon
Lyon, France
Sponsors and Collaborators
Hospices Civils de Lyon
Investigators
Principal Investigator: BRUNO LINA, MD,PhD Hospices Civils de Lyon
  More Information

No publications provided

Responsible Party: Pr Bruno LINA, Laboratoire de Virologie/Centre de Biologie et de Pathologie EST
ClinicalTrials.gov Identifier: NCT00830323     History of Changes
Other Study ID Numbers: 2008-517
Study First Received: January 26, 2009
Last Updated: September 29, 2010
Health Authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Additional relevant MeSH terms:
Communicable Diseases
Infection
Influenza, Human
Orthomyxoviridae Infections
RNA Virus Infections
Respiratory Tract Diseases
Respiratory Tract Infections
Virus Diseases
Amantadine
Oseltamivir
Zanamivir
Analgesics
Analgesics, Non-Narcotic
Anti-Dyskinesia Agents
Anti-Infective Agents
Antiparkinson Agents
Antiviral Agents
Central Nervous System Agents
Dopamine Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on November 20, 2014